In a single-center, retrospective study, researchers evaluated the effects of treatment with nDMTs compared with iDMTs in a cohort of patients with POMS.
Researchers sought to evaluate all-cause mortality at 30 days in patients with MS who were hospitalized at a VA center for COVID-19 between March 2020 and October 2021.
In a retrospective review, researchers sought to investigate the neurologic outcomes in patients with MS and related disorders following COVID-19 infection.
Using an analysis of combined data, researchers evaluated the dose-response relationship of 10, 20, and 40 mg ponesimod and the long-term safety and efficacy of poneismod 20 mg in patients with relapsing-remitting MS.
The researchers sought to determine whether the use of fluoxetine, riluzole, and amiloride led to an improvement in neuropathic pain compared with placebo in patients with SPMS in a trial.